Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.
Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.
复制标题
DOI：
10.1016/j.cellimm.2020.104214
复制
发表时间：
2020-11
影响因子：
4.3
通讯作者：
Issa F
中科院分区：
文献类型：
--
作者：
Alzhrani A;Bottomley M;Wood K;Hester J;Issa F
treg是免疫抑制最小化移植研究的主要焦点。异体抗原特异性treg的开发有可能提高疗效和安全性。存在许多生产方法，包括用供体同种异体抗原培养。多克隆Treg治疗的临床试验目前正进入II期及以上阶段。移植是受限于需要终身免疫抑制药物，这带来了显著的发病率和死亡率。调节性T细胞（Treg）治疗作为促进免疫抑制最小化的策略具有重要的前景。多克隆Treg疗法已经在实体器官和造血移植的I/II期临床试验中进行了评估。现在人们的注意力转向通过与供体抗原共培养产生异体抗原反应性Tregs （arTregs）。这些同种异体细胞具有强大的抑制功能，但它们的特异性意味着理论上脱靶效应的减少。本文将综述artreg的发展进展，包括其在移植临床应用中的潜在应用，从移植患者的临床试验中获得的知识，以及Treg治疗的未来方向。
Tregs are a major focus of investigation in transplantation for immunosuppression minimisation. Development of alloantigen-specific Tregs has the potential to improve efficacy and safety. A number of methodologies for production exist including culture with donor alloantigen. Clinical trials of polyclonal Treg therapy are now moving into Phase II and beyond. Transplantation is limited by the need for life-long pharmacological immunosuppression, which carries significant morbidity and mortality. Regulatory T cell (Treg) therapy holds significant promise as a strategy to facilitate immunosuppression minimization. Polyclonal Treg therapy has been assessed in a number of Phase I/II clinical trials in both solid organ and hematopoietic transplantation. Attention is now shifting towards the production of alloantigen-reactive Tregs (arTregs) through co-culture with donor antigen. These allospecific cells harbour potent suppressive function and yet their specificity implies a theoretical reduction in off-target effects. This review will cover the progress in the development of arTregs including their potential application for clinical use in transplantation, the knowledge gained so far from clinical trials of Tregs in transplant patients, and future directions for Treg therapy.
登录
查看更多内容
DOI：
10.1016/j.omtm.2018.01.006
发表时间：
2018-03-16
期刊：
Molecular therapy. Methods & clinical development
影响因子：
--
作者：
Fraser H;Safinia N;Grageda N;Thirkell S;Lowe K;Fry LJ;Scottá C;Hope A;Fisher C;Hilton R;Game D;Harden P;Bushell A;Wood K;Lechler RI;Lombardi G
通讯作者：
Lombardi G
影响因子：
8
作者：
Dawson, Nicholas A. J.;Lamarche, Caroline;Levings, Megan K.
通讯作者：
Levings, Megan K.
影响因子：
37.8
作者：
Hornick, PI;Mason, PD;Lechler, RI
通讯作者：
Lechler, RI
DOI：
10.1056/nejmoa1108188
发表时间：
2011-12-01
期刊：
The New England journal of medicine
影响因子：
--
作者：
Koreth J;Matsuoka K;Kim HT;McDonough SM;Bindra B;Alyea EP 3rd;Armand P;Cutler C;Ho VT;Treister NS;Bienfang DC;Prasad S;Tzachanis D;Joyce RM;Avigan DE;Antin JH;Ritz J;Soiffer RJ
通讯作者：
Soiffer RJ
影响因子：
4.4
作者：
Herrera, OB;Golshayan, D;Lechler, RI
通讯作者：
Lechler, RI